ArticleAnnals of Indian Academy of Neurology2026
Incidence, Predictors, and Outcomes of Symptomatic Intracranial Hemorrhage after Tenecteplase in Acute Ischemic Stroke.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSymptomatic intracranial hemorrhage (SICH) after thrombolysis is a major safety concern in the management of acute ischemic stroke (AIS). This study evaluates the predictors and outcomes of SICH among AIS patients receiving tenecteplase.
methodsThis multicenter retrospective observational study included AIS patients who received tenecteplase between December 2021 and June 2024 at 41 Swasthya Ingit Telestroke Network hospitals in West Bengal, India.
resultsOf 1,463 tenecteplase-treated AIS patients, 68 (4.64%) developed SICH. Mixed-effects multivariable logistic regression showed that age >61 years (adjusted odds ratio [aOR] 2.37, 95% confidence interval [CI] 1.38-4.07), hyperlipidemia (aOR 2.84, 95% CI 1.28-6.31), atrial fibrillation (aOR 4.84, 95% CI 1.86-12.59), smoking (aOR 2.55, 95% CI 1.30-5.00), systolic blood pressure >150 mmHg on admission (aOR 2.09, 95% CI 1.25-3.48), and a baseline National Institutes of Health Stroke Scale (NIHSS) score >9 (aOR 1.71, 95% CI 1.03-2.86) were associated with higher odds of SICH. An Alberta Stroke Program Early CT Score (ASPECTS) <8 was an additional risk factor among patients with middle cerebral artery (MCA) territory infarcts (aOR 3.32, 95% CI 1.70-6.50). Among the 313 patients who underwent angiography, the presence of large vessel occlusion was also associated with increased odds of SICH (aOR 5.65, 95% CI 1.86-17.19). In the SICH group, significantly fewer patients achieved a favorable outcome (mRS 0-2) at 90 days (7.4% vs 60.6%, P < 0.001), and all-cause mortality was significantly higher (79.4% vs 12.3%, P < 0.001).
conclusionsSICH after tenecteplase use in AIS is associated with increased morbidity and mortality. Older age, higher baseline NIHSS scores, elevated systolic blood pressure on admission, smoking, hyperlipidemia, atrial fibrillation, lower ASPECTS, and large vessel occlusion are associated with a higher risk of SICH in tenecteplase-treated AIS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.